Solidion Technology Inc. annual report, FY2023

Full document

Solidion Technology, Inc. — 2023 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. The business combination with Honeycomb Battery Company (HBC) closed on February 2, 2024, after year-end. Accordingly, the audited 2023 financial statements are those of Nubia, the pre-combination SPAC, not a full-year consolidation of HBC’s operating business. This distinction is important when interpreting the results.

Business context and financial highlights

  • Solidion develops battery materials, components and cells, including silicon-rich anodes and quasi-solid or solid-state battery technologies. At the reporting date, its business was early-stage and had not established significant commercial revenue.
  • Revenue and margins: The filing reports no operating revenue for the pre-combination company; margins are not meaningful. It separately describes HBC as having minimal sales.
  • Audited pre-combination results: 2023 net loss was $19.8 million, compared with net income of $0.6 million in 2022. Operating expenses were $3.5 million versus $0.9 million. The 2023 loss included an $18.5 million unfavorable change in fair value of derivative assets/liabilities, partly offset by $3.8 million of trust-account investment income. Income tax provision was $1.6 million.
  • Cash flow: The audited SPAC statements show $2.7 million of cash used in operating activities in 2023, versus $0.7 million in 2022. Separately, the filing says HBC/Solidion’s 2023 net loss was approximately $5.3 million and operating cash use approximately $4.1 million; those operating-business figures are not the same reporting scope as the audited Nubia statements.
  • Year-end liquidity: Nubia reported $20,000 of cash outside the trust and $43.0 million in the trust account at December 31, 2023, with a $6.5 million working-capital deficit. The filing separately cites approximately $1,000 of cash and cash equivalents for Solidion/HBC and states that recurring losses and funding needs raise substantial doubt about its ability to continue as a going concern. The text does not clearly reconcile these differing cash figures and reporting scopes.
  • Debt and obligations: At year-end, Nubia reported $1.3 million due under Sponsor convertible notes, $0.9 million of related-party convertible notes, $0.3 million of related-party advances and $0.2 million of advances from HBC. A $2.2 million note for underwriters’ fees was entered into in February 2024, with scheduled payments through March 2025.

Material changes and subsequent financing

  • Redemptions reduced trust assets substantially during 2023. Trust cash and investments fell from $127.8 million at December 31, 2022 to $43.0 million at December 31, 2023; the business combination then closed in February 2024.
  • The company reports $1.6 million of net proceeds from the business combination, before transaction and issuance costs. On March 15, 2024, it closed a private placement for approximately $3.85 million in gross proceeds, before fees and expenses, issuing common stock or pre-funded warrants and additional warrants.
  • After the combination, HBC became a wholly owned subsidiary and the company was renamed Solidion Technology, Inc. The filing reports 86.9 million common shares outstanding as of April 11, 2024. It also states G3 held approximately 85.3% of voting power and identifies substantial potential resale and dilution from securities covered by registration rights.

Outlook, commentary and key risks

  • Management’s plans rely on external financing; the filing gives no assurance that additional debt or equity will be available on acceptable terms. The going-concern uncertainty is emphasized by both management and the auditor, whose opinion includes a going-concern paragraph.
  • Company targets include scaling silicon-anode capacity from 15 metric tons per year to more than 150 by 2026; introducing Gen 1 and Gen 2 cells in 2026 and Gen 3 in 2027; and a proposed graphite facility with 10,000 metric tons of annual capacity by 2026. The filing estimates $100–$200 million of capital expenditure for that facility and projected revenue of $90–$100 million. These are forward-looking plans, not achieved results or committed guidance.
  • Commercialization depends on successful technical development, extensive safety testing, customer qualification, equipment availability and production scale-up. Management also cites long equipment lead times and the need for custom-designed equipment.
  • Principal risks include continuing losses and limited liquidity, execution and manufacturing scale-up, product safety or performance failures, competition and technology changes, customer adoption and lengthy OEM sales cycles, supplier and raw-material constraints, intellectual-property disputes, regulatory and environmental compliance, and potential dilution.
  • Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2023 because cash withdrawn from the trust account for tax obligations was used for operating purposes rather than promptly remitted or held as restricted cash. The filing says the tax payable was recorded and intended for payment; it also states that approximately $82,000 was remitted in the first quarter of 2024. The auditor did not attest to internal-control effectiveness.
  • The filing reports no material litigation pending. It also notes the company’s public warrants were delisted from Nasdaq and were pending OTC Markets listing under STIW.

Important facts for investors to verify

  1. Reconcile the separate Nubia/SPAC and HBC/Solidion financial figures, especially year-end cash, operating cash use and losses, and confirm the post-combination cash balance and current runway.
  2. Confirm the terms, net proceeds and dilution from the March 2024 financing, Sponsor-related notes, the $2.2 million underwriter note, warrants and registration rights.
  3. Track actual progress against production, customer qualification, safety-testing and commercialization milestones, and the funding required to meet them.
  4. Review the status of the tax remittance and any remediation of the disclosed control weakness; distinguish management’s control assessment from the auditor’s financial-statement opinion.
  5. Assess the implications of G3’s voting control, potential share sales, Nasdaq listing status and the status of the public warrants.